Quantitative proteomics analysis of platelet-derived microparticles reveals distinct protein signatures when stimulated by different physiological agonists

Journal of Proteomics

Volumn 121, Issue , 2015, Pages 56-66

  Milioli, Marco ^a   Ibáñez Vea, Maria ^b   Sidoli, Simone ^b,d   Palmisano, Giuseppe ^c   Careri, Maria ^a   Larsen, Martin R ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Agonist strength; Mass spectrometry; Platelet activation; Platelet derived microparticles; Proteomics

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN; PROTEASOME; THROMBIN; ACTIN; PHOSPHATE; PROTEIN; PROTEOME;

ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DEGRANULATION; GLYCOLYSIS; HEART INFARCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; PENTOSE PHOSPHATE CYCLE; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE ANALYSIS; RESPIRATORY CHAIN; THROMBOCYTE ACTIVATION; CELL COMMUNICATION; CHEMISTRY; CLUSTER ANALYSIS; CYTOLOGY; CYTOSKELETON; ELECTROSPRAY MASS SPECTROMETRY; MEMBRANE MICROPARTICLE; METABOLISM; PROTEIN DATABASE; TANDEM MASS SPECTROMETRY; THROMBOCYTE;

ACTINS; ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; CELL COMMUNICATION; CELL-DERIVED MICROPARTICLES; CLUSTER ANALYSIS; COLLAGEN; CYTOSKELETON; DATABASES, PROTEIN; HUMANS; PHOSPHATES; PLATELET ACTIVATION; PROTEINS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; THROMBIN;

EID: 84926679441     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.03.013     Document Type: Article

References (64)

1. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967, 13:269-288.
2. Zwaal R.F., Comfurius P., Bevers E.M. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992, 1180:1-8.
3. Heijnen H.F., Schiel A.E., Fijnheer R., Geuze H.J., Sixma J.J. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999, 94:3791-3799.
4. Daniel L., Fakhouri F., Joly D., Mouthon L., Nusbaum P., Grunfeld J.P., et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 2006, 69:1416-1423.
5. Lynch S.F., Ludlam C.A. Plasma microparticles and vascular disorders. Br J Haematol 2007, 137:36-48.
6. Flaumenhaft R., Dilks J.R., Richardson J., Alden E., Patel-Hett S.R., Battinelli E., et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009, 113:1112-1121.
7. Castaman G., Yu-Feng L., Rodeghiero F. A bleeding disorder characterised by isolated deficiency of platelet microvesicle generation. Lancet 1996, 347:700-701.
8. Nomura S., Uehata S., Saito S., Osumi K., Ozeki Y., Kimura Y. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 2003, 89:506-512.
9. Joop K., Berckmans R.J., Nieuwland R., Berkhout J., Romijn F.P., Hack C.E., et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001, 85:810-820.
10. Sheremata W.A., Jy W., Horstman L.L., Ahn Y.S., Alexander J.S., Minagar A. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008, 5:27.
11. Knijff-Dutmer E.A., Koerts J., Nieuwland R., Kalsbeek-Batenburg E.M., van de Laar M.A. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002, 46:1498-1503.
12. Janowska-Wieczorek A., Marquez-Curtis L.A., Wysoczynski M., Ratajczak M.Z. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2006, 46:1199-1209.
13. Kim H.K., Song K.S., Park Y.S., Kang Y.H., Lee Y.J., Lee K.R., et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003, 39:184-191.
14. Biró E., Akkerman J.W., Hoek F.J., Gorter G., Pronk L.M., Sturk A., et al. The phospholipid composition and cholesterol content of platelet-derived microparticles: a comparison with platelet membrane fractions. J Thromb Haemost 2005, 3:2754-2763.
15. Morel O., Jesel L., Freyssinet J.M., Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011, 31:15-26.
16. Schoenwaelder S.M., Yuan Y., Josefsson E.C., White M.J., Yao Y., Mason K.D., et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009, 114:663-666.
17. Cranmer S.L., Ashworth K.J., Yao Y., Berndt M.C., Ruggeri Z.M., Andrews R.K., et al. High shear-dependent loss of membrane integrity and defective platelet adhesion following disruption of the GPIbα-filamin interaction. Blood 2011, 117:2718-2727.
18. Gemmell C.H., Sefton M.V., Yeo E.L. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem 1993, 268:14586-14589.
19. Yuana Y., Bertina R.M., Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011, 105:396-408.
20. Meissner F., Mann M. Quantitative shotgun proteomics: considerations for a high-quality workflow in immunology. Nat Immunol 2014, 15:112-117.
21. Han X., Aslanian A., Yates J.R. Mass spectrometry for proteomics. Curr Opin Chem Biol 2008, 12:483-490.
22. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
23. Capriotti A.L., Caruso G., Cavaliere C., Piovesana S., Samperi R., Laganà A. Proteomic characterization of human platelet-derived microparticles. Anal Chim Acta 2013, 776:57-63.
24. Dean W.L., Lee M.J., Cummins T.D., Schultz D.J., Powell D.W. Proteomic and functional characterisation of platelet microparticle size classes. Thromb Haemost 2009, 102:711-718.
25. Perez-Pujol S., Marker P.H., Key N.S. Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A 2007, 71:38-45.
26. Shai E., Parguiña A.F., Motahedeh S., Varon D., Garcia A. Comparative analysis of platelet-derived microparticles reveals differences in their amount and proteome depending on the platelet stimulus. J Proteomics 2012, 76:287-296.
27. Aatonen M, Öhman, T, Nyman TA, Laitinen, S, Grönholm, M, Siljander P. Isolation and characterization of platelet-derived extracellular vesicles. Journal Extracell vesicles doi: doi:10.3402/jev.v3.24692.
28. Aatonen M., Grönholm M., Siljander P. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 2012, 38:102-113.
29. Smid M., Dielis A.W.J.H., Winkens M., Spronk H.M.H., van Oerle R., Hamulyák K. Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 2011, 9:450-456.
30. Carcaillon L., Alhenc-Gelas M., Bejot Y., Spaft C., Ducimetière P., Ritchie K., et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol 2011, 31:1445-1451.
31. de Bruijne E.L., Gils A., Rijken D.C., de Maat M.P., Guimarães A.H., Poldermans D., et al. High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res 2011, 127:254-258.
32. De Candia E. Mechanisms of platelet activation by thrombin: a short history. Thromb Res 2012, 129:250-256.
33. Bevers E.M., Comfurius P., Zwaal R.F. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983, 736:57-66.
34. Keuren J.F., Wielders S.J., Ulrichts H., Hackeng T., Heemskerk J.W., Deckmyn H., et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol 2005, 25:1499-1505.
35. Palmisano G., Lendal S.E., Engholm-Keller K., Leth-Larsen R., Parker B.L., Larsen M.R. Selective enrichment of sialic acid-containing glycopeptides using titanium dioxide chromatography with analysis by HILIC and mass spectrometry. Nat Protoc 2010, 5:1974-1982.
36. Thingholm T.E., Palmisano G., Kjeldsen F., Larsen M.R. Undesirable charge-enhancement of isobaric tagged phosphopeptides leads to reduced identification efficiency. J Proteome Res 2010, 9:4045-4052.
37. Brosch M., Yu L., Hubbart T., Choudhary J. Accurate and sensitive peptide identification with Mascot Percolator. J Proteome Res 2009, 8:3176-3181.
38. Franceschini A., Szklarczyk D., Frankild S., Kuhn M., Simonovic M., Roth A., et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013, 41:D808-D815.
39. Fujiki Y., Hubbard A.L., Fowler S., Lazarow P.B. Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J Cell Biol 1982, 93:97-102.
40. Woronowicz K., Dilks J.R., Rozenvayn N., Dowal L., Blair P.S., Peters C.G., et al. The platelet actin cytoskeleton associates with SNAREs and participates in alpha-granule secretion. Biochemistry 2010, 49:4533-4542.
41. Dale G.L., Remenyi G., Friese P. Tetraspanin CD9 is required for microparticle release from coated-platelets. Platelets 2009, 20:361-366.
42. Slupsky J.R., Seehafer J.G., Tang S.C., Masellis-Smith A., Shaw A.R.E. Evidence that monoclonal antibodies against CD9 antigen induce specific association between CD9 and the platelet glycoprotein IIb-IIIa complex. J Biol Chem 1989, 264:12289-12293.
43. Nieswandt B., Moser M., Pleines I., Varga-Szabo D., Monkley S., Critchley D., et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med 2007, 204:3113-3118.
44. Pollard T.D. Regulation of actin filament assembly by Arp2/3 complex and formins. Annu Rev Biophys Biomol Struct 2007, 36:451-477.
45. Mouneimne G., Hansen S.D., Selfors L.M., Petrak L., Hickey M.M., Gallegos L.L., et al. Differential remodeling of actin cytoskeleton architecture by profilin isoforms leads to distinct effects on cell migration and invasion. Cancer Cell 2012, 22:615-630.
46. Kristensen L.P., Larsen M.R., Mickley H., Saaby L., Diederichsen A.C., Lambrechtsen J., et al. Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin. J Proteomics 2014, 101:141-153.
47. Bigalke B., Schuster A., Sopova K., Wurster T., Stellos K. Platelets in atherothrombosis-diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases. Curr Vasc Pharmacol 2012, 10:589-596.
48. Doery J.C., Hirsh J., Cooper I. Energy metabolism in human platelets: interrelationship between glycolysis and oxidative metabolism. Blood 1970, 36:159-168.
49. McDonald B., Reep B., Lapetina E.G., Vedia L.M. Glyceraldehyde-3-phosphate dehydrogenase is required for the transport of nitric oxide in platelets. Proc Natl Acad Sci U S A 1993, 90:11122-11126.
50. Moon J.S., Kim H.E., Koh E., Park S.H., Jin W.J., Park B.W., et al. Krüppel-like factor 4 (KLF4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (PFKP) in breast cancer. J Biol Chem 2011, 286:23808-23816.
51. Lecker S.H., Goldberg A.L., Mitch W.E. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006, 17:1807-1819.
52. Gupta N., Li W., Willard B., Silverstein R.L., McIntyre T.M. Proteasome proteolysis supports stimulated platelet function and thrombosis. Arterioscler Thromb Vasc Biol 2014, 34:160-168.
53. Huang J.S., Ramamurthy S.K., Lin X., Le Breton G.C. Cell signalling through thromboxane A2 receptors. Cell Signal 2004, 16:521-533.
54. Sasaki M., Sukegawa J., Miyosawa K., Yanagisawa T., Ohkubo S., Nakahata N. Low expression of cell-surface thromboxane A2 receptor β-isoform through the negative regulation of its membrane traffic by proteasomes. Prostaglandins Other Lipid Mediat 2007, 83:237-249.
55. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H. Platelet mitochondria function in Parkinson's disease. Ann Neurol 1992, 32:782-788.
56. Murray J., Taylor S.W., Zhang B., Ghosh S.S., Capaldi R.A. Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry. J Biol Chem 2003, 278:37223-37230.
57. Coppinger J.A., Cagney G., Toomey S., Kislinger T., Belton O., McRedmond J.P., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004, 103:2096-2104.
58. Kinlough-Rathbone R.L., Perry D.W., Guccione M.A., Rand M.L., Packham M.A. Degranulation of human platelets by the thrombin receptor peptide SFLLRN: comparison with degranulation by thrombin. Thromb Haemost 1993, 70:1019-1023.
59. Fateh-Moghadam S., Li Z., Ersel S., Reuter T., Htun P., Plöckinger U., et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol 2005, 25:1299-1303.
60. Janes S.L., Wilson D.J., Cox A.D., Chronos N.A., Goodall A.H. ADP causes partial degranulation of platelets in the absence of aggregation. Br J Haematol 1994, 86:568-573.
61. Dobaczewski M., Gonzalez-Quesada C., Frangogiannis N.G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010, 48:504-511.
62. Parguiña A.F., Grigorian-Shamajian L., Agra R.M., Teijeira-Fernández E., Rosa I., Alonso J., et al. Proteins involved in platelet signaling are differentially expressed in acute coronary syndrome: a proteomic study. PLoS One 2010, 5:e13404.
63. Pimanda J.E., Ganderton T., Maekawa A., Yap C.L., Lawler J., Kershaw G., et al. Role of thrombospondin-1 in control of von Willebrand Factor Multimer size in mice. J Biol Chem 2004, 279:21439-21448.
64. Tasneem S., Adam F., Minullina I., Pawlikowska M., Hui S.K., Zheng S., et al. Platelet adhesion to multimerin 1 in vitro: influences of platelet membrane receptors, von Willebrand factor and shear. J Thromb Haemost 2009, 7:685-692.